AXOLTIS PHARMA
Axoltis pharma is a biotech company that develops drugs for degenerative and traumatic neurological disorders.
AXOLTIS PHARMA
Social Links:
Industry:
Biotechnology Health Care Pharmaceutical
Founded:
2003-01-01
Address:
Lyon, Rhone-Alpes, France
Country:
France
Website Url:
http://www.axoltis.com
Total Employee:
1+
Status:
Active
Contact:
+33 (0)472 621 736
Email Addresses:
[email protected]
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Google Tag Manager Euro Google Font API Google Analytics Google Maps WordPress
Similar Organizations
ARCEDI Biotech
ARCEDI Biotech is a biotech company, develops technologies and methods for detecting and diagnosing rare cancer cells.
NephroDI Therapeutics
NephroDI Therapeutics is a biopharmaceutical company that focuses on the concentration disorders of the kidney.
PCI Pharma Services
PCI Pharma Services is a provider of outsourced services to the global pharmaceutical market.
Prolocor
Prolocor is a biotechnology company that develops diagnostic tests for cardiovascular diseases.
Synaxys
Synaxys is a research company for drug discovery for neurological diseases.
Trevarx Biomedical
Trevarx Biomedical is a biomedical startup that develops new radiopharmaceuticals.
Current Employees Featured
Founder
Official Site Inspections
http://www.axoltis.com Semrush global rank: 9.99 M Semrush visits lastest month: 286
- Host name: cluster020.hosting.ovh.net
- IP address: 46.105.57.169
- Location: Saint-Ouen France
- Latitude: 48.9067
- Longitude: 2.3339
- Timezone: Europe/Paris
- Postal: 93400
More informations about "Axoltis pharma"
www.axoltis.com
We would like to show you a description here but the site won’t allow us.See details»
Axoltis pharma - Crunchbase Company Profile & Funding
Organization. Axoltis pharma . Connect to CRM . Save . Summary. People. Technology. Signals & News. Similar Companies. ... Axoltis pharma is located …See details»
Axoltis Pharma - LinkedIn
Axoltis pharma is a biopharmaceutical company dedicated to develop a first-in-class disease-modifying drug to treat patients with neurodegenerative or traumatic neurological disorders …See details»
Axoltis Pharma Company Profile 2024: Valuation, Funding
Axoltis Pharma General Information Description. Operator of a biotechnology company intended to treat patients suffering from severe neurological disorders. The company's drugs assist …See details»
Axoltis Pharma SA - Drug pipelines, Patents, Clinical trials - Synapse
Axoltis Pharma is a French biopharmaceutical company dedicated to developing a first-in-class disease-modifying drug to treat patients with neurodegenerative or traumatic neurological …See details»
Axoltis Pharma - Craft
Axoltis Pharma has 5 employees across 2 locations. See insights on Axoltis Pharma including office locations, competitors, revenue, financials, executives, subsidiaries and more at Craft.See details»
Axoltis pharma - Contacts, Employees, Board Members
Axoltis pharma is a biotech company that develops drugs for degenerative and traumatic neurological disorders.See details»
AXOLTIS PHARMA Company Profile - Dun & Bradstreet
Find company research, competitor information, contact details & financial data for AXOLTIS PHARMA of CLERMONT FERRAND, AUVERGNE RHONE ALPES. Get the latest business …See details»
Axoltis Pharma CEO and Key Executive Team | Craft.co
Axoltis Pharma's Chief Executive Officer is Yann Godfrin. Other executives include Valérie Bourdes, Chief Medical Officer; Sébastien Marie, Clinical Operations Director and 1 others. …See details»
Axoltis Pharma - VentureRadar
Similar Companies: Nosopharm France n/a Nosopharm is an innovative biotechnology company headquartered in Lyon (France) and specialized in the research and development of new …See details»
Axoltis Pharma receives authorization to launch SEALS – phase II ...
Apr 10, 2024 Axoltis Pharma, a French biopharma company, develops innovative drugs for neurodegenerative and neurotraumatic diseases with a high unmet medical need. …See details»
Axoltis Pharma presents promising results from phase 1b clinical …
Axoltis recently presented these phase 1b results, combined with encouraging findings from the company’s preclinical studies, at Neuroscience 2023, the annual meeting of the Society for …See details»
Axoltis Pharma receives authorization to launch SEALS
Clermont-Ferrand and Lyon, France, April 10, 2024 – Axoltis Pharma, a French biopharmaceutical company dedicated to developing therapeutic solutions for neurodegenerative diseases, today …See details»
ALS candidate NX210c is safe, well tolerated in healthy volunteer...
Jan 3, 2024 “We are very pleased with our preclinical and clinical studies, which strengthen Axoltis’ position to become a key leader in BBB repair. Among our target applications is the …See details»
InSilicoTrials and Axoltis Pharma Collaborate to Advance …
Axoltis Pharma is a French biopharmaceutical company dedicated to developing a first-in-class disease-modifying drug to treat pa-tients with neurodegenerative or traumatic neurological …See details»
NX-210c - Drug Targets, Indications, Patents - Synapse - Patsnap
Nov 21, 2024 NX-210c, Initially developed by Axoltis Pharma SA, Now, its global highest R&D status is Phase 2, Therapeutic Areas: Nervous System Diseases,Endocrinology and Metabolic …See details»
Axoltis Pharma receives authorization to launch SEALS – phase II ...
Apr 10, 2024 Axoltis Pharma, a French biopharma company, develops innovative drugs for neurodegenerative and neurotraumatic diseases with a high unmet medical need. …See details»
Drug candidate for ALS patients authorised for Phase II trial
Apr 16, 2024 Axoltis aims to enrol a total of 80 ALS patients in a trial planned in France with at least 15 investigating sites. Patients will receive a 10-minute IV infusion of the study drug at …See details»
InSilicoTrials and Axoltis Pharma Collaborate to Advance …
Jul 27, 2023 Given that Axoltis drug candidate NX210c targets these features, the collaboration with InSilicoTrials holds great promise for supporting CNS functions in a wide range of …See details»
InSilicoTrials and Axoltis Pharma Announce Collaboration
Jul 28, 2023 InSilicoTrials has embarked on a collaborative partnership with Axoltis Pharma, a biopharmaceutical company committed to developing disease-modifying drugs for patients …See details»